Feature Story:

Data Published in The Lancet Compare Dabigatran Etexilate to Dose-Adjusted Warfarin Across RE-LY® Trial Centers

- Sub-analysis shows no significant interaction between trial centers’ time in therapeutic range and stroke with either dose of dabigatran etexilate compared to warfarin¹ -

Ridgefield, CT, August 29, 2010 — Boehringer Ingelheim today announced results from a pre-specified, retrospective, un-blinded sub-analysis of the RE-LY® trial – the largest atrial fibrillation outcomes trial ever conducted2 – were published in The Lancet.  The sub-analysis evaluated the primary outcomes of RE-LY® in relation to each center’s average time in therapeutic range (cTTR) (INR 2.0-3.0) for patients taking warfarin.¹